“Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s476. doi:10.25251/skin.8.supp.476.